In recent years, immunoadsorption has been increasingly recognized as an alternative to
therapeutic plasma exchange and used for the treatment of neurological disorders such as …

Most of the diseases for which apheresis therapy is indicated are intractable and rare, and
each patient has a different background and treatment course prior to apheresis therapy …

Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease
caused by JC virus (JCV), predominantly affecting patients with impaired cellular immunity …

Background Since there has been no conclusive evidence regarding the treatment of ocular
myasthenia, treatment guidelines were recently issued by the European Federation of …

Background Neurological disorders with IgG antibodies against myelin-oligodendrocyte
glycoprotein (MOG-IgG) have been increasingly recognised as a new type of …

Objective Myasthenia gravis (MG) is an autoimmune disease mostly caused by
autoantibodies against acetylcholine receptor associated with thymus abnormalities …

Background Patients with anti-aquaporin-4 (AQP4) water channel antibody-positive
neuromyelitis optica spectrum disorders (AQP4-NMOSD) and myelin oligodendrocyte …

Background The most attentive clinical problem in patients with branch atheromatous
disease (BAD) is early neurological deterioration (END). Although the platelet activation …

Introduction Plasmapheresis is a well‐recognized treatment for autoimmune neurological
diseases in Japan. However, the practice varies depending on the facility, and the actual …

To illustrate the accuracy of the fluorescence-activated cell sorting cell-based assay (FACS-
CBA) and to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies and …